Protacs In 2025: From The Laboratory Concept To Clinical Breakthrough

Proteolysis-Targeting Chimeras (PROTACs) have significantly transformed drug discovery by utilizing a unique catalytic degradation mechanism that targets and degrades specific proteins. This technology has progressed from a laboratory concept to achieving clinical breakthroughs, demonstrating its potential in treating various diseases. PROTACs offer advantages over traditional inhibitors by providing sustained protein degradation, which can lead to more effective and durable therapeutic outcomes. The development of PROTACs has opened new avenues for targeting previously "undruggable" proteins, marking a pivotal advancement in the field of medicinal chemistry and pharmacology.